AdBio Partners SAS. (9/4/23). "Press Release: AdBio Partners Appoints Laurence de Schoulepnikoff as Venture Partner". Paris.

	Organisation	AdBio Partners SAS (AFB)
	Group	AdBio Partners (Group)
	Organisation 2	Tridek-One Therapeutics SAS
	Product	venture capital
	Product 2	CD31 agonist (immune checkpoint agonist)
	Person	de Schoulepnikoff, Laurence (Tridek-One 202207– CEO before Amal Therapeutics)
	Person 2	de Ribains, Geoffroy (AdBio Partners 202302– promoted to Managing Parnter joined AFB 2009 before Step Pharma + Biomunex)

AdBio partners, a venture capital company specialized in seed investments in life sciences startups, today announces that it has appointed Laurence de Schoulepnikoff as Venture Partner.

In this new role, Laurence de Schoulepnikoff will be working as non-executive director on the boards of companies of AdBio portfolio.

Laurence is a seasoned pharma/biotech professional with a broad experience in corporate strategy, business development & transactions and R&D operations. She holds a Master’s in Chemical Engineering from the Ecole Polytechnique Federale of Lausanne (EPFL) and brings more than 25 years’ experience in the pharma industry in VC funded biotech start-ups, large corporate organizations and mid-size private companies.

Laurence is currently CEO of Tridek-One, a biotech start-up developing first-in-class CD31 agonist modalities designed to restore the immune balance.

“I am delighted and grateful to have the opportunity to support AdBio partners portfolio companies. I look forward to putting my skills and experience advising companies as a member of their board of directors.” says Laurence de Schoulepnikoff.

“We are very pleased to welcome Laurence on board, her deep experience as executive in the biotech sector will be very valuable for our companies” adds Geoffroy de Ribains, Managing Partner at AdBio partners.

About AdBio partners

AdBio partners (previously Advent France Biotechnology) is an AMF-regulated (the French financial market authority) company that invests in a range of sectors within life sciences - specifically in therapeutics-oriented projects.

Its unique strategy combines early-stage investments in promising enterprises and strong entrepreneurial support to strengthen the company’s growth.

Created in 2016, AdBio partners has made 23 European investments in France, Belgium, Spain and Ireland with two funds AFB Seed Fund I and AFB FII.

AdBio partners has developed strong relationships within the European innovation ecosystem; as a result, it has attracted international VC syndicates to its portfolio companies.

The operational team includes investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise.

www.adbio.partners

Press and analyst contacts

[email protected]

Record changed: 2024-09-12